Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Time-resolved FTIR study on the structural switching of human galectin-1 by light-induced disulfide bond formation.

Kuroi K, Kamijo M, Ueki M, Niwa Y, Hiramatsu H, Nakabayashi T.

Phys Chem Chem Phys. 2019 Nov 27. doi: 10.1039/c9cp04881b. [Epub ahead of print]

PMID:
31774080
2.

Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.

Iwamoto N, Aruga T, Horiguchi S, Saita C, Onishi M, Goto R, Ishiba T, Honda Y, Miyamoto H, Kuroi K.

Surg Today. 2019 Jul 31. doi: 10.1007/s00595-019-01858-x. [Epub ahead of print]

PMID:
31367884
3.

Effects of molecular crowding environment on the acquisition of toxic properties of wild-type SOD1.

Takahashi A, Nagao C, Murakami K, Kuroi K, Nakabayashi T.

Biochim Biophys Acta Gen Subj. 2020 Feb;1864(2):129401. doi: 10.1016/j.bbagen.2019.07.010. Epub 2019 Jul 23.

PMID:
31348988
4.

[Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer].

Iwamoto N, Aruga T, Miyamoto H, Saita C, Onishi M, Goto R, Ishiba T, Honda Y, Kuroi K.

Gan To Kagaku Ryoho. 2019 Jul;46(7):1137-1140. Japanese.

PMID:
31296819
5.

Examination of the association states of dehydroergosterol towards understanding the association structures of sterols in a membrane.

Kuroi K, Imaizumi M, Miura T, Nakabayashi T.

Biochem Biophys Res Commun. 2019 Jul 12;515(1):228-233. doi: 10.1016/j.bbrc.2019.05.109. Epub 2019 May 27.

PMID:
31146916
6.

Ultrasound-guided fine-needle aspiration of axillary lymph nodes in breast cancer: Diagnostic accuracy and role in surgical management.

Iwamoto N, Aruga T, Horiguchi S, Asami H, Saita C, Onishi M, Goto R, Ishiba T, Honda Y, Miyamoto H, Kuroi K.

Diagn Cytopathol. 2019 Aug;47(8):788-792. doi: 10.1002/dc.24203. Epub 2019 Apr 30.

PMID:
31041851
7.

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.

Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M.

ESMO Open. 2019 Feb 27;4(1):e000476. doi: 10.1136/esmoopen-2018-000476. eCollection 2019.

8.

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.

Fujiwara Y, Mukai H, Saeki T, Ro J, Lin YC, Nagai SE, Lee KS, Watanabe J, Ohtani S, Kim SB, Kuroi K, Tsugawa K, Tokuda Y, Iwata H, Park YH, Yang Y, Nambu Y.

Br J Cancer. 2019 Mar;120(5):475-480. doi: 10.1038/s41416-019-0391-z. Epub 2019 Feb 12.

9.

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.

Breast Cancer. 2019 Sep;26(5):535-543. doi: 10.1007/s12282-019-00952-9. Epub 2019 Feb 7.

10.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.

Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M.

Breast Cancer Res Treat. 2018 Dec;172(3):611-618. doi: 10.1007/s10549-018-4958-9. Epub 2018 Sep 7.

PMID:
30194511
11.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study.

Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M.

Breast Cancer (Auckl). 2018 Jul 5;12:1178223418786243. doi: 10.1177/1178223418786243. eCollection 2018.

12.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial.

Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M.

ESMO Open. 2018 Feb 14;3(2):e000314. doi: 10.1136/esmoopen-2017-000314. eCollection 2018.

13.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial.

Masuda N, Toi M, Yamamoto N, Iwata H, Kuroi K, Bando H, Ohtani S, Takano T, Inoue K, Yanagita Y, Kasai H, Morita S, Sakurai T, Ohno S.

Breast Cancer. 2018 Jul;25(4):407-415. doi: 10.1007/s12282-018-0839-7. Epub 2018 Feb 14.

14.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
15.

Change in the structure and function of lectin by photodissociation of NO.

Kurota T, Sato I, Kuroi K, Hiramatsu H, Nakabayashi T.

Chem Commun (Camb). 2017 Sep 16;53(72):10014-10017. doi: 10.1039/c7cc04795a. Epub 2017 Aug 24.

PMID:
28835961
16.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M.

N Engl J Med. 2017 Jun 1;376(22):2147-2159. doi: 10.1056/NEJMoa1612645.

17.

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.

Chow LWC, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CYC, Loo WTY, Glück S, Toi M.

Asia Pac J Clin Oncol. 2017 Dec;13(6):372-378. doi: 10.1111/ajco.12682. Epub 2017 Mar 28.

PMID:
28371190
18.

Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.

Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K.

Breast Cancer Res Treat. 2017 Apr;162(3):501-510. doi: 10.1007/s10549-017-4138-3. Epub 2017 Feb 8.

PMID:
28181129
19.

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.

Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Hattori S, Matsuura Y, Kuroi K.

Breast Cancer Res Treat. 2017 Feb;161(3):473-482. doi: 10.1007/s10549-016-4075-6. Epub 2016 Dec 22.

PMID:
28005247
20.

Anomalous pressure effects on the photoreaction of a light-sensor protein from Synechocystis, PixD (Slr1694), and the compressibility change of its intermediates.

Nakajima T, Kuroi K, Nakasone Y, Okajima K, Ikeuchi M, Tokutomi S, Terazima M.

Phys Chem Chem Phys. 2016 Sep 21;18(37):25915-25925.

PMID:
27711633
21.

Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer.

Sawada T, Araki J, Yamashita T, Masubuchi M, Chiyoda T, Yunokawa M, Hoshi K, Tao S, Yamamura S, Yatsushiro S, Abe K, Kataoka M, Shimoyama T, Maeda Y, Kuroi K, Tamura K, Sawazumi T, Minami H, Suda Y, Koizumi F.

EBioMedicine. 2016 Sep;11:173-182. doi: 10.1016/j.ebiom.2016.07.027. Epub 2016 Jul 27.

22.

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.

Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M.

BMC Cancer. 2016 Mar 16;16:230. doi: 10.1186/s12885-016-2270-9.

23.

Time-resolved fluctuation during the photochemical reaction of a photoreceptor protein: phototropin1LOV2-linker.

Kuroi K, Sato F, Nakasone Y, Zikihara K, Tokutomi S, Terazima M.

Phys Chem Chem Phys. 2016 Feb 17;18(8):6228-38. doi: 10.1039/c5cp07472j.

PMID:
26854261
24.

Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.

Saita C, Goto R, Aruga T, Idera N, Honda Y, Horiguchi K, Miyamoto H, Horiguchi S, Yamashita T, Kuroi K.

BMC Res Notes. 2016 Jan 26;9:46. doi: 10.1186/s13104-016-1854-4.

25.

Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer.

Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, Toi M.

Ann Surg Oncol. 2016 Jan;23(1):44-50. doi: 10.1245/s10434-015-4809-4. Epub 2015 Aug 15.

PMID:
26275781
26.

Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.

Honda Y, Aruga T, Yamashita T, Miyamoto H, Horiguchi K, Kitagawa D, Idera N, Goto R, Kuroi K.

Jpn J Clin Oncol. 2015 Aug;45(8):713-8. doi: 10.1093/jjco/hyv067. Epub 2015 May 15.

PMID:
25981620
27.

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.

Inoue K, Kuroi K, Shimizu S, Rai Y, Aogi K, Masuda N, Nakayama T, Iwata H, Nishimura Y, Armour A, Sasaki Y.

Int J Clin Oncol. 2015 Dec;20(6):1102-9. doi: 10.1007/s10147-015-0832-5. Epub 2015 May 13.

28.

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer.

Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.

Cancer Sci. 2015 Jun;106(6):734-9. doi: 10.1111/cas.12658. Epub 2015 Apr 9.

29.

Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients.

Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M.

Int J Clin Oncol. 2015 Aug;20(4):723-4. doi: 10.1007/s10147-015-0814-7. No abstract available.

PMID:
25772578
30.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients.

Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, Takano T, Takada M, Yasuno S, Morita S, Toi M.

Int J Clin Oncol. 2015 Aug;20(4):709-22. doi: 10.1007/s10147-015-0785-8. Epub 2015 Feb 10. Erratum in: Int J Clin Oncol. 2015 Aug;20(4):723-4. Sato, Nobuki [corrected to Sato, Nobuaki].

PMID:
25666483
31.

Pressure-sensitive reaction yield of the TePixD blue-light sensor protein.

Kuroi K, Okajima K, Ikeuchi M, Tokutomi S, Kamiyama T, Terazima M.

J Phys Chem B. 2015 Feb 19;119(7):2897-907. doi: 10.1021/jp511946u. Epub 2015 Jan 28.

PMID:
25601594
32.

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

Ito Y, Masuda N, Iwata H, Mukai H, Horiguchi J, Tokuda Y, Kuroi K, Mori A, Ohno N, Noguchi S.

Gan To Kagaku Ryoho. 2015 Jan;42(1):67-75. Japanese.

PMID:
25596682
33.

Transient conformational fluctuation of TePixD during a reaction.

Kuroi K, Okajima K, Ikeuchi M, Tokutomi S, Terazima M.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14764-9. doi: 10.1073/pnas.1413222111. Epub 2014 Sep 29.

34.

Comparison of outcomes between women with de novo stage IV and relapsed breast cancer.

Kitagawa D, Horiguchi S, Yamashita T, Kuroi K, Shimizu K.

J Nippon Med Sch. 2014;81(3):139-47.

35.

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.

Masuda N, Higaki K, Takano T, Matsunami N, Morimoto T, Ohtani S, Mizutani M, Miyamoto T, Kuroi K, Ohno S, Morita S, Toi M.

Cancer Chemother Pharmacol. 2014 Aug;74(2):229-38. doi: 10.1007/s00280-014-2492-y. Epub 2014 May 29.

PMID:
24871032
36.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Ando M, Yamauchi H, Aogi K, Shimizu S, Iwata H, Masuda N, Yamamoto N, Inoue K, Ohono S, Kuroi K, Hamano T, Sukigara T, Fujiwara Y.

Breast Cancer Res Treat. 2014 Jun;145(2):401-9. doi: 10.1007/s10549-014-2947-1. Epub 2014 Apr 12.

PMID:
24728578
37.

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).

Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M.

Breast Cancer Res Treat. 2014 May;145(1):143-53. doi: 10.1007/s10549-014-2907-9. Epub 2014 Mar 30.

38.

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG.

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.

Breast Cancer. 2015 Nov;22(6):586-95. doi: 10.1007/s12282-014-0524-4. Epub 2014 Feb 27.

39.

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG.

Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F.

Breast Cancer. 2015 Sep;22(5):486-95. doi: 10.1007/s12282-013-0511-1. Epub 2013 Dec 14.

PMID:
24338638
40.

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.

Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M.

Breast Cancer Res Treat. 2013 Nov;142(1):69-80.

41.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.

Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M.

Int J Clin Oncol. 2014 Aug;19(4):607-13. doi: 10.1007/s10147-013-0614-x. Epub 2013 Oct 8.

42.

Anomalous diffusion of TePixD and identification of the photoreaction product.

Kuroi K, Tanaka K, Okajima K, Ikeuchi M, Tokutomi S, Terazima M.

Photochem Photobiol Sci. 2013 Jul;12(7):1180-6. doi: 10.1039/c3pp25434h.

PMID:
23535998
43.

An overview of the Japan Breast Cancer Research Group (JBCRG) activities.

Ohno S, Kuroi K, Toi M.

Breast Cancer. 2013 Oct;20(4):291-5. doi: 10.1007/s12282-012-0420-8. Epub 2013 Mar 15. Review.

44.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.

Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13.

45.

[Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)].

Masuda N, Toi M, Kuroi K.

Nihon Rinsho. 2012 Sep;70 Suppl 7:763-72. Japanese. No abstract available.

PMID:
23350501
46.

[Anti-Her2 therapy in breast cancer].

Kuroi K.

Nihon Rinsho. 2012 Sep;70 Suppl 7:606-13. Japanese. No abstract available.

PMID:
23350472
47.

[The significance for prognostic factor of pathological complete response (pCR) after neoadjuvant chemotherapy].

Kitagawa D, Kuroi K.

Nihon Rinsho. 2012 Sep;70 Suppl 7:162-5. Japanese. No abstract available.

PMID:
23350385
48.

Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life 2 years after breast cancer surgery.

Taira N, Shimozuma K, Ohsumi S, Kuroi K, Shiroiwa T, Watanabe T, Saito M.

Breast Cancer. 2014 Mar;21(2):183-90. doi: 10.1007/s12282-012-0374-x. Epub 2012 Aug 30.

PMID:
22932759
49.

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).

Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T.

Int J Clin Oncol. 2013 Aug;18(4):598-606. doi: 10.1007/s10147-012-0437-1. Epub 2012 Jul 26.

PMID:
22833344
50.

[A case of primary breast cancer responding to pre-operative chemotherapy with the combination of paclitaxel and carboplatin for ovarian cancer].

Kitagawa D, Nako Y, Honda Y, Shigekawa T, Horiguchi K, Aruga T, Yamashita T, Kuroi K.

Gan To Kagaku Ryoho. 2012 Jun;39(6):1013-6. Japanese.

PMID:
22705705

Supplemental Content

Support Center